Stem cells havent exactly panned out as hoped when it comes to approved therapeutics. There are only a couple that have received a nod from the FDA in very specific indications. But the ongoing COVID-19 pandemic could push stem cells back into the limelight and more firmly establish them as therapeutically relevant.
There are at least a few dozen trials looking at various types of stem cells to treat different aspects of COVID-19 in patients in different states of disease severity. Cleveland-based Athersys Inc. has started a large, pivotal clinical study to enroll up to 400 COVID-19 patients to treat those with moderate to severe acute respiratory distress syndrome (ARDS) with its Multistem candidate, which is available frozen, off-the-shelf and derived from the bone marrow of adult donors.
Building on ARDS data
A small phase I/II study of Multistem to treat ARDS in non-COVID patients previously reported positive results, shortening the average time on a ventilator and in an intensive care unit (ICU).
Although underpowered, there was a signal there that the cell-based therapy may be beneficial. In the randomized, placebo-controlled, blinded portion of the study, the cell-based therapy was associated with a decrease in ICU days and ventilator day and decreased mortality, Frank Jacono, who is an associate professor of medicine and a pulmonary and critical care medicine physician at University Hospitals Cleveland and the Cleveland VA Medical Center, told BioWorld of the phase I/II results. If anything, that signal was strongest in the sickest of the patients. Basically, that is the foundation for the evaluation of COVID-19 moderate to severe ARDS.
Jacono participated as a site investigator in the phase I/II trial and is the site principal investigator for the newly started phase II/III study of Multistem to treat COVID-19 induced, moderate to severe ARDS.
Multistem has been investigated in various neurological, inflammatory and immune, as well as cardiovascular and other critical care indications, but it has not gained FDA approval. The most advanced indication for the stem cell candidate is to treat patients after an ischemic stroke; it is in a phase III clinical trial in that indication.
In May 2019, Athersys received fast track designation from the FDA for the Multistem for the treatment of ARDS. There are no FDA-approved drugs to treat this indication.
The phase I/II study, known as MUST-ARDS, started with the examination of two doses, first 300 million cells in three patients and then 900 million cells in three patients. The subsequent randomized, double-blinded, placebo-controlled 30-patient trial randomized patients 2:1 to intravenous administration of 900 million Multistem cells vs. placebo.
The study was primarily a safety study and not powered for efficacy results. However, it did find lower mortality, particularly for more severe ARDS patients; improved quality of life; fewer days on a ventilator (12.9 vs. 9.2 with placebo); and more intensive-care free days (10.3 vs. 8.1 with placebo). Among a prospectively defined group of severe ARDS patients in that study, average ventilator-free days were 14.6 vs. 8 in the placebo subgroup and mean ICU-free days were 11.4 vs. 5.9 days with placebo. These were all assessed after 28 days.
Multiple mechanisms
The mechanisms of action for Multistem is not pathogen-specific, of course, so it would potentially work to help the immune system function more effectively to reduce the severe lung inflammation that leads to ARDS. This would include SARS-COV-2, as well as any secondary bacterial pneumonia infection in the same patient.
Multistem is thought to express factors that work to reduce inflammation, protect damaged or injured tissue and enhance the formation of new blood vessels after injury. They are believed to have a drug-like profile in regulating the immune system and promoting system repair. The candidate is expected to decrease the activation of the peripheral immune system, thereby reducing tissue damage and scarring and accelerating repair processes.
The product is frozen, so it could eventually be deployed widely in lots of different hospital settings because of the company's formulation, said Jacono. Sometimes, when people hear stem cells, they think about stem cells going in and repopulating and growing into new cells that would then replace the old cells in the patient. That's not what's hypothesized here.
The stem cells will enter the circulation and go to the lungs. It's hoped that they would express factors to help restore and re-regulate the immune response in the lungs transitioning back from a damaging type of response to a more beneficial response and then leave the body, he continued. But they don't persist in the body, they don't set up and grow new cells, they don't replace cells; they just act to sort of modulate the immune response while they're there.
The recently started phase II/III trial will again start with a dose-ranging precursor. The studys large enrollment size could mean that it could take a couple of years to get to the results. The inherently unpredictable nature of the ebb and flow of the number of COVID-19 infections, as well as the concurrently shifting availability of other treatments and testing of other candidates, make it difficult to assess how motivated patients and their families will be to enroll in the phase II/III trial.
Known as MACOVIA, the primary efficacy endpoint is the number of ventilator-free days through day 28 vs. placebo. Secondary endpoints include 60-day all-cause mortality, time in the intensive care unit, pulmonary function, tolerability and quality of life among survivors after one year.
Other recent small clinical trials provide some reason to hope for some success with stem cells in COVID-19 treatment. These include a 12-patient study of another allogeneic stem cell therapy, remestemcel-L from Mesoblast Ltd., recently reported positive data treating ventilator-dependent COVID-19 patients with moderate to severe ARDS. A phase II/III study is slated to follow. A seven-patient evaluation of compassionate use of an allogeneic, mesenchymal-like cell therapy from Pluristem Therapeutics Inc. in COVID-19 patients also showed promise.
The expectation for Multistem is that, regardless of the path of the pandemic, the pivotal trial will provide further insight into the usefulness of the candidate in treating moderate to severe ARDS from any cause, which had been the focus previously.
We want to study this carefully and scientifically, summed up Jacono. But at the end, we'll be confident as a result whether or not this is beneficial for patients and should be considered more routinely as part of therapy.
Read the original:
- Storage conditions affect the composition of the lyophilized secretome of multipotent mesenchymal stromal cells ... - Nature.com - May 4th, 2024
- Mesenchymal Stem Cells Market Will Increase USD 10 Billion By 2033 - PharmiWeb.com - May 4th, 2024
- Mesenchymal stem cell based therapies for uveitis: a systematic review of preclinical studies | Eye - Nature.com - April 10th, 2024
- Development of exosome therapy to treat inflammatory bowel disease by VesiCURE Therapeutics - StreetInsider.com - April 10th, 2024
- Adipose Derived Stem Cell Therapy Market Will Show the Highest Growth Rates, Incredible Demand by 2031 - WhaTech - April 3rd, 2024
- Injectable microspheres adhering to the cartilage matrix promote rapid reconstruction of partial-thickness cartilage defects - ScienceDirect.com - March 30th, 2024
- Safety and Potential Effect of Intrauterine Infusion of Autologous Adipose Tissue-Derived Regenerative Cells in ... - Cureus - March 30th, 2024
- Instructing iPS cell-derived mesenchymal stem cells to inhibit abnormal bone formation in FOP - Medical Xpress - March 28th, 2024
- Clinical application of mesenchymal stem cell in regenerative medicine ... - March 22nd, 2024
- Mesenchymal Stem Cells: The Past Present and Future - March 22nd, 2024
- CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General ... - Yahoo Finance - March 20th, 2024
- Overexpression of Wnt5a promoted the protective effect of mesenchymal stem cells on Lipopolysaccharide-induced ... - BMC Infectious Diseases - March 20th, 2024
- Mesenchymal Stem Cells: What We Have Learned and How to Manage Them - MDPI - March 17th, 2024
- Mesenchymal stem cells and their microenvironment - March 17th, 2024
- Mesenchymal stem/stromal cells as a valuable source for the treatment ... - March 17th, 2024
- Proteomic characterization of hUC-MSC extracellular vesicles and evaluation of its therapeutic potential to treat ... - Nature.com - March 13th, 2024
- The impact understanding of exosome therapy in COVID-19 and preparations for the future approaches in dealing with ... - Nature.com - March 13th, 2024
- CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to ... - Yahoo Finance UK - March 7th, 2024
- CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to ... - Yahoo Finance - March 6th, 2024
- Combatting osteoarthritis with cartilage replacement therapy - Drug Target Review - March 3rd, 2024
- Ethical considerations in Stem Cell therapy for ALS - Cyprus Mail - February 27th, 2024
- Therapeutic Solutions International Files Patent on Facilitating Effects of JadiCells on Gene Therapy Mediated Cell ... - Business Wire - February 27th, 2024
- Stem Cell Therapy for Ulcerative Colitis - Health Central - February 27th, 2024
- Expanding the Horizons of Cell and Gene Therapy - RegMedNet - February 24th, 2024
- Early differentiation of mesenchymal stem cells is reflected in their dielectrophoretic behavior | Scientific Reports - Nature.com - February 22nd, 2024
- Orthopaedics Department's Regenerative Research Highlighted at ORS Annual Meeting - InventUM - University of Miami - February 20th, 2024
- Cellular uptake and in vivo distribution of mesenchymal-stem-cell-derived extracellular vesicles are protein corona ... - Nature.com - February 18th, 2024
- New University spin-out developing novel adult stem cell-based Therapies - News - University of Liverpool - News - February 15th, 2024
- Examining the potential of the common bovine as a potential therapeutic research model - Medical Xpress - February 15th, 2024
- Intentional Interference: Genetic Engineering Medium Aids The Transfection Of MSCs With siRNA - BioProcess Online - February 15th, 2024
- Cellular senescence is associated with osteonecrosis of the femoral head while mesenchymal stem cell conditioned ... - Nature.com - February 9th, 2024
- Stem Cell Therapy for Crohns Disease Shows Promising Results - RegMedNet - February 9th, 2024
- Targeted transcriptomic analysis of synovial tissues from horses with septic arthritis treated with immune-activated ... - American Veterinary Medical... - February 7th, 2024
- Mesenchymal Stem Cell Immunomodulation: Mechanisms and ... - Cell Press - February 7th, 2024
- New Cell Therapy for ARDS: A Groundbreaking Development and Other Respiratory Health Breakthroughs - Medriva - February 7th, 2024
- Effective treatment of optic neuropathies by intraocular delivery of MSC-sEVs through augmenting the G-CSF ... - pnas.org - January 31st, 2024
- Global Stem Cell Therapy Industry Outlook to 2028, Driven by Therapeutic Innovations and Clinical Advancements ... - Yahoo Finance - January 29th, 2024
- Out-of-this-world study will test how stem cells function in space - YP - January 29th, 2024
- The Applications of Cell Therapy - Technology Networks - January 26th, 2024
- STEM CELL THERAPY FOR MS COST: WHAT YOU NEED TO KNOW? - Island Echo - January 24th, 2024
- Understanding Neuromyelitis Optica: Role of NF-B and Therapeutic Potential - Medriva - January 20th, 2024
- Faculty member Arnold Caplan passes away The Daily The Daily - The Daily | Case Western Reserve University - January 18th, 2024
- Effects of fine particulate matter on bone marrow-conserved hematopoietic and mesenchymal stem cells: a systematic ... - Nature.com - January 11th, 2024
- Expression of HLA-DR by mesenchymal stromal cells in the platelet lysate era: an obsolete release criterion for MSCs ... - Journal of Translational... - January 11th, 2024
- NurOwn and its exosomes for ALS given patents in Europe, elsewhere - ALS News Today - January 8th, 2024
- Single-cell analysis reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of ovarian ... - Nature.com - January 8th, 2024
- First in Class Combination Stem Cell and Exosome Therapy to Treat Pulmonary Fibrosis in Long Haul Covid Patients ... - Yahoo Finance - January 4th, 2024
- Choosing the Right Excipients for MSC and iPSC Therapies - Pharmaceutical Technology Magazine - January 4th, 2024
- Mitochondria Transplantation Therapy It's Farther Along Than You Think - BioProcess Online - January 2nd, 2024
- Embryonic-stem-cell-derived mesenchymal stem cells relieve experimental contact urticaria by regulating the functions ... - Nature.com - December 21st, 2023
- Type I collagen and fibromodulin enhance the tenogenic phenotype of hASCs and their potential for tendon ... - Nature.com - December 19th, 2023
- Could the 'central dogma' of biology be misleading bioengineers? - Phys.org - December 13th, 2023
- The Risks of Stem Cell and Exosome Treatments for Long COVID: A Call for Stricter Regulations - Medriva - December 13th, 2023
- Mesenchymal stem cells from biology to therapy - PMC - December 11th, 2023
- The Safety and Efficacy of Human Umbilical Cord-Derived ... - Cureus - December 5th, 2023
- The pivotal role of Nrf2 signal axis in IDD | JIR - Dove Medical Press - December 5th, 2023
- Futuristic Novel Therapeutic Approaches in the Treatment of ... - Cureus - December 3rd, 2023
- Cartilage's Contribution in Otology: A Comprehensive Review of Its ... - Cureus - December 3rd, 2023
- Mesenchymal stem or stromal cells: a review of clinical applications ... - November 29th, 2023
- Comparative evaluation of 3D-printed and conventional implants in ... - Nature.com - November 29th, 2023
- Expression of E-cadherin and N-cadherin in Epithelial-to ... - Cureus - November 29th, 2023
- Enhancing the immunosuppressive properties of human umbilical cord mesenchymal stem cells - Phys.org - November 29th, 2023
- 'Great Potential' in Stem Cell Therapies for Knee Osteoarthritis ... - Pain News Network - November 25th, 2023
- Dietary Sources, Bioavailability, and Functions of Ascorbic Acid ... - Cureus - November 25th, 2023
- FY 2024 VA-Funded Projects - VA's Office of Research and Development - November 25th, 2023
- Real-world data suggest effectiveness of the allogeneic ... - Journal of Translational Medicine - November 23rd, 2023
- Mesenchymal Stem Cells: Characteristics, Function, and Application - November 23rd, 2023
- Combined application of therapeutic viruses and nanomaterials to ... - News-Medical.Net - November 23rd, 2023
- Progress in the Development of Stem Cell-Derived Cell-Free ... - Dove Medical Press - November 23rd, 2023
- Improving the therapeutic efficacy of oncolytic viruses for cancer ... - Journal of Translational Medicine - November 23rd, 2023
- 11.22.23 -- How To Lose A Batch In 10 Days - BioProcess Online - November 23rd, 2023
- The Pros and Cons of Mesenchymal Stem Cell-Based Therapies - November 19th, 2023
- Leptin's influence on MMP-1 expression | JIR - Dove Medical Press - November 15th, 2023
- TWIST1 and TSG6 are coordinately regulated and function as ... - Science - November 11th, 2023
- Association between severe acute malnutrition in childhood and ... - BioMed Central - November 11th, 2023
- Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders - Yahoo Finance - November 11th, 2023
- Stem Cell Restore Reviews - Does It Work? Real Green Valley ... - The Daily World - November 11th, 2023
- Biological and genetic characterization of a newly established ... - Nature.com - November 11th, 2023
- Placental Stem Cell Collection and Storage Industry Scope ... - Argyle Report - November 9th, 2023
- In Vitro Evaluation of Light-Induced Cytotoxic Property: Synergistic ... - Cureus - November 9th, 2023
Recent Comments